

# Sex-specific determinants of HIV infection among injection drug users in Montreal

Julie Bruneau,<sup>\*†</sup> François Lamothe,<sup>‡</sup> Julio Soto,<sup>§</sup> Nathalie Lachance,<sup>‡</sup> Jean Vincelette,<sup>‡</sup> Anne Vassal,<sup>‡</sup> Eduardo L. Franco<sup>¶</sup>

## Abstract

**Background:** Sex-specific issues have not been extensively addressed in studies of HIV prevalence, despite the strong implications of differences between men and women in the risk of HIV transmission. The objective of this study was to examine sex-specific behaviours associated with HIV infection among injection drug users in Montreal.

**Methods:** A total of 2741 active drug users (2209 [80.6%] men) were recruited between 1988 and 1998. Information was sought on sociodemographic characteristics, drug-related behaviour and sexual behaviour, and participants were tested for HIV antibodies. Sex-specific independent predictors of HIV prevalence were assessed by stepwise logistic regression.

**Results:** The overall prevalence of HIV among study subjects was 11.1%; the prevalence was 12.0% among men and 7.5% among women. In multivariate models, a history of sharing syringes with a known seropositive partner (odds ratio [OR] for men 2.44, 95% confidence interval [CI] 1.72–3.46; OR for women 3.03, 95% CI 1.29–7.13) and of sharing syringes in the past 6 months (OR for men 0.61, 95% CI 0.44–0.85; OR for women 0.32, 95% CI 0.14–0.73) were independently associated with HIV infection. Other variables associated with HIV infection were homosexual or bisexual orientation, cocaine rather than heroin as drug of choice, frequency of injection drug use, and obtaining needles at a pharmacy or through needle exchange programs (for men only) and obtaining needles at shooting galleries and being out of treatment (for women only).

**Interpretation:** These results support the hypothesis that risk factors for HIV seropositivity differ between men and women. These sex-related differences should be taken into account in the development of preventive and clinical interventions.

During the past decade, injection drug use has been recognized as one of the major routes of HIV transmission in Canada. For example, approximately half of the estimated 3000 to 5000 new HIV infections identified in Canada in 1996 occurred in injection drug users.<sup>1</sup> Among women, the proportion of reported AIDS cases attributed to injection drug use has increased dramatically, from 6.4% in 1990 to 38.9% in 1998.<sup>2</sup>

Many cross-sectional studies<sup>3–20</sup> have identified factors associated with HIV infection among injection drug users. Several studies have found a high risk of HIV infection among those who inject primarily cocaine,<sup>3–5</sup> those who inject frequently<sup>6–10</sup> and those who attend shooting galleries.<sup>5,7,10–13</sup> Injection drug users also engage in high-risk sexual behaviours, such as sex with multiple partners, inconsistent use of condoms and prostitution, but these behaviours have not been consistently associated with HIV infection.<sup>14–16</sup> Characteristics of a disorganized lifestyle, such as unstable housing,<sup>8,17</sup> injecting outdoors<sup>18,19</sup> and being imprisoned,<sup>6,20</sup> were independently associated with a higher risk of HIV infection.

Sex-specific issues have not been extensively addressed in prevalence studies, despite the strong implications of a differential between men and women in the

## Research

## Recherche

From the Departments of \*Family Medicine, †Psychiatry, and ‡Microbiology and Infectious Diseases, Centre hospitalier de l'Université de Montréal, Montreal, Que.; the §Public Health Department, Montreal-Centre, Montreal, Que.; and the ¶Department of Epidemiology and Biostatistics, McGill University, Montreal, Que.

*This article has been peer reviewed.*

CMAJ 2001;164(6):767-73

‡ See related article page 802

risk of HIV transmission. Several authors have reported differences between the sexes in the social settings of injection, perceptions of risk and protection mechanisms,<sup>14,21,22</sup> but not in relation to HIV prevalence. Female injection drug users reportedly often had regular sexual partners who inject drugs,<sup>23,24</sup> and those obtaining used equipment did so predominantly from a sexual partner.<sup>25</sup> The role of the family, particularly the spouse, in determining needle-sharing behaviour was more important among women than among men.<sup>26</sup>

In 1988 we began a longitudinal study in downtown Montreal to monitor risk factors associated with HIV infection among active injection drug users. This report, based on data from the study, examines sex-specific behavioural patterns associated with HIV infection among injection drug users.

## Methods

Injection drug users who had injected in the past 6 months and were residing in the greater Montreal area were eligible to participate; all participants gave informed consent. Participants were recruited from several sources: by self-referral (64.2% of the men and 44.5% of the women), from the Saint-Luc Detoxification Unit (18.2% of the men and 42.9% of the women), from collaborating institutions (3.4% of the men and 2.8% of the women) and from other sources such as health care centres and private physicians (14.1% of the men and 10.0% of the women).

At study entry, a trained nurse interviewed the participants using a structured questionnaire. After pretest counselling, a 30-mL blood sample was obtained by venipuncture for HIV antibody testing. During each visit, for which a stipend of \$10 was given, referrals were provided for universal medical care, HIV/AIDS care, drug and alcohol treatment, and counselling. Recruitment to the study has been stable since 1988, and on average 23 new subjects are enrolled each month. In this paper, we report results from the entry questionnaire for 2741 participants recruited from Sept. 15, 1988, to Oct. 1, 1998.

The baseline questionnaire elicited detailed information for periods of the past month, the previous 6 months and the person's lifetime. Specifically, it covered sociodemographic characteristics, history of drug use, current drug use, injection behaviour, acquisition of syringes, sexual behaviour, utilization of health and addiction treatment services, previous HIV testing and reported results, and medical history. For the purposes of this study, sharing syringes was defined as reuse of blood-contaminated syringes.

Serological screening for HIV antibodies was performed in the microbiology laboratory at Saint-Luc Hospital, Centre hospitalier de l'Université de Montréal, with an enzyme-linked immunosorbent assay (ELISA). All samples that tested positive were retested by ELISA, and such results were confirmed by the Western blot technique, performed at the Laboratoire de santé publique du Québec in Montreal.

Data for men and women were analyzed separately. Sociodemographic, drug consumption and sexual behaviour variables were compared according to the serostatus of participants at enrolment. Logistic regression was used to calculate crude odds ratios (ORs) and 95% confidence intervals (CIs) for categories of each variable. For ordinal variables, a dose-response trend test was based on the Wald statistic.

For each sex, independent factors associated with HIV prevalence at baseline were assessed by stepwise logistic regression. Only the most informative variables were used at this stage, as determined by substantive knowledge, preliminary univariate analysis and assessment of collinearity. Although no correlation coefficient greater than 0.6 was found, time since first injection was the only time-related variable considered in the stepwise procedure for both models. We used *p* values of 0.10 and 0.15 for inclusion and removal of variables respectively. To account for potential historical trends, we assessed all interactions between entry period (3 categories) and each variable in the final models.

## Results

From Sept. 15, 1988, to Oct. 1, 1998, 2741 subjects (2209 men and 532 women) consented to participate in the study, completed the baseline questionnaire and provided a venous sample for HIV testing. Median age at entry was 32 (range 14–63) years; the median age for women was lower than that for men (30 v. 34 years). French was the mother tongue for 2189 (79.9%) of the participants; English was the mother tongue for another 378 (13.8%). Most participants were single (2299 [83.9%]) and unemployed (2518 [91.9%]), and 1572 (57.4%) had less than 12 years of education. Mean duration of injection drug use was 9.8 years. Of the 304 participants who tested positive for HIV, 176 (57.9%) had been previously tested, and 84 (27.6%) were aware of their seropositive status before the enrolment interview. The prevalence of HIV antibody was 11.1% (95% CI 10.0% to 12.3%) for all subjects, 12.0% (95% CI 10.7% to 13.4%) for men, and 7.5% (95% CI 5.6% to 10.1%) for women.

Table 1 shows the crude ORs for HIV seropositivity at entry and the variables independently associated with HIV infection for men. Male subjects who were seropositive at study entry were older than those who were seronegative at entry, were more likely to have French as their mother tongue and were more likely to have less than high school education. Cocaine rather than heroin as the drug of choice was strongly associated with seropositivity at entry. Reported sharing of syringes (for both lifetime and over the past 6 months) was high among both HIV-positive and HIV-negative subjects, and 1594 (72.2%) of the male subjects reported sharing at least once in the past 6 months. After adjustment for other factors, male injection drug users who had shared syringes in the previous 6 months were at lower risk of being HIV positive (OR 0.61, 95% CI 0.44–0.85 [Table 1]). However, in a reanalysis excluding the 76 HIV-positive subjects who were aware of their seropositive status at the time of recruitment, there was no relation between sharing syringes and HIV seropositivity (OR 0.82, 95% CI 0.57–1.21).

Analyses to identify changes in the effects of variables over time showed that the period when the subject entered the study affected the relation between use of a pharmacy for obtaining syringes and seropositive status. The OR for HIV-positive status given use of a pharmacy was 16.3 (95%

CI 2.1–126.0) for the subset of injection drug users recruited between September 1988 and December 1991, whereas the same OR for subjects recruited between January 1992 and October 1998 was 1.24 (95% CI 0.80–1.88).

**Table 1: Sociodemographic, drug consumption and sexual behaviour variables associated with HIV seropositivity at study entry among 2209 male injection drug users in Montreal**

Variable	No. of subjects	No. (and %) HIV positive	Crude analysis, OR (and 95% CI)	Multivariate analysis, OR (and 95% CI)
<b>Sociodemographic characteristics</b>				
<i>Period of entry into study</i>				
Sept. 1988 to Dec. 1991	527	58 (11.0)	1.0	1.0
Jan. 1992 to June 1995	860	108 (12.6)	1.16 (0.83–1.63)	0.86 (0.58–1.29)
July 1995 to Oct. 1998	822	98 (11.9)	1.09 (0.78–1.55)	0.54 (0.34–0.85)
Trend test			$p = 0.69$	
<i>Language (mother tongue)</i>				
French	1768	235 (13.3)	1.0	1.0
English	295	26 (8.8)	0.63 (0.41–0.96)	0.72 (0.45–1.15)
Other	146	3 (2.1)	0.14 (0.04–0.43)	0.24 (0.07–0.78)
<i>HIV-positive acquaintances</i>				
0	984	60 (6.1)	1.0	1.0
≥1	1225	205 (16.7)	3.08 (2.28–4.16)	2.19 (1.53–3.13)
<b>Drug-related behaviour</b>				
<i>Drug of choice</i>				
Heroin	437	16 (3.7)	1.0	1.0
Cocaine	1467	222 (15.1)	4.69 (2.79–7.89)	4.41 (2.40–7.14)
Other	305	26 (8.5)	2.45 (1.29–4.65)	3.27 (1.64–6.52)
<i>Time since first injected drugs, yr</i>				
< 3	552	46 (8.3)	1.0	1.0
3–7	525	68 (13.0)	1.64 (1.10–2.43)	1.30 (0.84–2.01)
8–15	530	72 (13.6)	1.73 (1.17–2.56)	1.37 (0.89–2.12)
≥ 16	602	78 (13.0)	1.64 (1.11–2.40)	1.24 (0.80–1.92)
Trend test			$p = 0.02$	$p = 0.40$
<i>No. of injections in past month</i>				
0	435	28 (6.4)	1.0	1.0
1–29	687	75 (10.9)	1.78 (1.13–2.80)	1.82 (1.12–2.94)
30–100	610	84 (13.8)	2.32 (1.48–3.63)	2.12 (1.28–3.50)
> 100	477	77 (16.1)	2.80 (1.78–4.40)	2.26 (1.35–3.78)
Trend test			$p < 0.001$	$p = 0.004$
<i>Shared syringes* in past 6 mo</i>				
No	615	80 (13.0)	1.0	1.0
Yes	1594	183 (11.5)	0.87 (0.66–1.16)	0.61 (0.44–0.85)
<i>Ever shared syringes outside Montreal</i>				
No	1718	215 (12.5)	1.0	1.0
Yes	491	49 (10.0)	0.78 (0.56–1.08)	0.58 (0.40–0.84)
<i>Ever shared syringes with HIV-positive person</i>				
No or don't know	1910	182 (9.5)	1.0	1.0
Yes	295	82 (27.8)	3.66 (2.72–4.93)	2.44 (1.72–3.46)
<i>Obtained syringes at pharmacy in past 6 mo</i>				
No	473	37 (7.8)	1.0	1.0
Yes	1736	227 (13.1)	1.77 (1.23–2.55)	1.48 (0.99–2.20)
<i>Obtained syringes from NEP in past 6 mo</i>				
No	1094	75 (6.9)	1.0	1.0
Yes	1115	190 (17.0)	2.77 (2.09–3.68)	2.12 (1.56–2.89)
<i>History of drug consumption in prison</i>				
Never imprisoned	546	39 (7.1)	1.0	1.0
Imprisoned but never injected drugs	1484	194 (13.1)	1.97 (1.37–2.82)	1.61 (1.08–2.40)
Imprisoned and injected drugs with or without sharing syringes	179	30 (16.8)	2.62 (1.57–4.36)	2.52 (1.40–4.52)
<b>Sexual behaviour</b>				
<i>Sexual orientation</i>				
Heterosexual	2003	208 (10.4)	1.0	1.0
Homosexual or bisexual	206	56 (27.2)	3.22 (2.30–4.52)	2.46 (1.64–3.71)
<i>No. of sex partners in past 6 mo</i>				
0	929	126 (13.6)	1.0	1.0
1	457	49 (10.7)	0.77 (0.54–1.09)	0.69 (0.45–1.07)
≥ 2	823	89 (10.8)	0.77 (0.58–1.03)	0.51 (0.35–0.73)
<i>Ever been a prostitute</i>				
No	1806	179 (9.9)	1.0	1.0
Yes	398	85 (21.4)	2.48 (1.86–3.29)	1.53 (1.08–2.17)

Note: OR = odds ratio, CI = confidence interval, NEP = needle exchange program.

\*Reused a syringe already used by someone else.

Table 2 shows the crude ORs of HIV seropositivity at entry and the variables independently associated with HIV infection for women. In unadjusted analyses, female subjects who acquired syringes through needle exchange programs had a higher risk of being HIV seropositive (crude OR 1.93, 95% CI 1.00–3.75). This was also true for women who acquired their syringes at shooting galleries (crude OR 3.07, 95% CI 1.32–7.15), although women who obtained their syringes from pharmacies and dealers were not at increased risk of HIV seropositivity. In the adjusted model, only acquisition of syringes at a shooting gallery was associated with a higher risk of HIV seropositivity, although this finding was of borderline sig-

nificance (Table 2; OR 2.51, 95% CI 0.88–7.19,  $p = 0.09$ ).

According to multivariate analyses, sharing syringes with a known seropositive partner was the only variable positively associated with HIV infection for both men and women. Sharing syringes in the past 6 months was negatively associated with prevalence of HIV for both sexes.

### Interpretation

In our study, HIV seroprevalence was higher among men (12.0%, 95% CI 10.7% to 13.4%) than among women (7.5%, 95% CI 5.6% to 10.1%). We postulate that this difference might be due to differential self-selection

**Table 2: Sociodemographic, drug consumption and sexual behaviour variables associated with risk of HIV seropositivity at study entry among 532 female injection drug users in Montreal**

Variable	No. of subjects	No. (and %) HIV positive	Crude analysis, OR (and 95% CI)	Multivariate analysis, OR (and 95% CI)
<b>Sociodemographic characteristics</b>				
<i>Period of entry into study</i>				
Sept. 1988 to Dec. 1991	145	15 (10.3)	1.0	1.0
Jan. 1992 to June 1995	196	8 (4.1)	0.37 (0.15–0.90)	0.32 (0.11–0.90)
July 1995 to Oct. 98	191	17 (8.9)	0.85 (0.41–1.76)	0.51 (0.21–1.29)
Trend test			$p = 0.76$	$p = 0.25$
<b>Drug-related behaviour</b>				
<i>Drug of choice</i>				
Heroin	216	9 (4.2)	1.0	1.0
Cocaine	261	28 (10.7)	2.77 (1.27–5.99)	1.94 (0.81–4.62)
Other	55	3 (5.5)	1.33 (0.35–5.08)	0.63 (0.13–3.02)
<i>Time since first injected drugs, yr</i>				
< 3	204	4 (2.0)	1.0	1.0
3–7	130	8 (6.2)	3.27 (0.97–11.1)	3.54 (0.97–12.9)
8–15	133	20 (15.0)	8.84 (2.95–26.5)	7.38 (2.14–25.4)
≥ 16	65	8 (12.3)	7.00 (2.04–24.1)	4.56 (1.14–18.3)
Trend test			$p < 0.001$	$p = 0.008$
<i>Shared syringes in past 6 mo</i>				
No	131	14 (10.7)	1.0	1.0
Yes	401	26 (6.5)	0.58 (0.29–1.15)	0.32 (0.14–0.73)
<i>Ever shared syringes with HIV-positive person</i>				
No or don't know	462	26 (5.6)	1.0	1.0
Yes	69	14 (20.3)	4.27 (2.11–8.68)	3.03 (1.29–7.13)
<i>Obtained syringes in shooting gallery in past 6 mo</i>				
No	487	32 (6.6)	1.0	1.0
Yes	45	8 (17.8)	3.07 (1.32–7.15)	2.51 (0.88–7.19)
<i>Currently out of treatment</i>				
No	330	21 (6.4)	1.0	1.0
Yes	202	19 (9.4)	1.54 (0.80–2.92)	2.94 (1.30–6.66)
<i>History of drug consumption in prison</i>				
Never imprisoned	320	10 (3.1)	1.0	1.0
Imprisoned but never injected drugs	207	28 (13.5)	4.85 (2.30–10.2)	1.94 (0.81–4.64)
Imprisoned and injected drugs with or without sharing syringes	5	2 (40.0)	20.70 (3.10–137.30)	4.44 (0.39–50.3)
<b>Sexual behaviour</b>				
<i>Sexual intercourse in prison</i>				
No or not applicable*	510	33 (6.5)	1.0	1.0
Yes	22	7 (31.8)	6.74 (2.57–17.7)	3.23 (0.98–10.7)

\*Not applicable indicates that subject was never imprisoned.

bias: recruited women were younger than men, a greater proportion of women than men reported heroin as their drug of choice (39.2% v. 19.5%), and a greater proportion of women than men were in treatment (62.0% v. 37.2%).

Duration of injection drug use was associated with HIV prevalence among women but not men in the multivariate model. Use of cocaine (rather than heroin) was independently associated with HIV prevalence among men, a finding that corroborated previous findings.<sup>5,7,9</sup> We therefore hypothesized that heavy cocaine users may become infected earlier in the course of their injection history. Cocaine use as an independent risk factor for HIV infection cannot be explained solely by related risk behaviours and might be attributable to unmeasured factors, such as patterns of drug use and high-risk behaviours during cocaine binges. Users who inject cocaine often describe losing both insight and control while on binges, which could lead them to inject more of the drug and to take greater sexual risks. Such behaviours might not have been captured by our structured questionnaire.

Injection drug users in Montreal have access to sterile equipment without prescription through pharmacies, needle exchange programs and other sources. Despite the fact that reuse of syringes was not associated with prevalence of HIV, sharing syringes was reported frequently by both HIV-positive and HIV-negative subjects, an unexpected finding in a setting where needles and syringes are legally accessible. Aside from misclassification, this finding may reflect the persistence of high-risk behaviour among injection drug users in a setting where low-cost cocaine is readily accessible. This is especially likely during sporadic periods when needles are unavailable from needle exchange programs. In this study, sharing syringes in the past 6 months was negatively associated with HIV prevalence among both sexes. This finding can be partially explained by the fact that knowledge of HIV status influences equipment-sharing behaviour. In analyses excluding subjects who knew that they were HIV positive, there was no significant risk associated with sharing needles and syringes (OR including all subjects 0.61, 95% CI 0.44–0.85; OR excluding 76 HIV-positive subjects who knew their HIV status 0.82, 95% CI 0.57–1.21).

HIV-positive men were more likely than HIV-negative men to report obtaining their syringes at a pharmacy or from needle exchange programs. In addition, HIV-positive men entering the study before 1991 (the early days of needle exchange programs) were more likely to obtain syringes from a pharmacy than those entering the study in the later entry periods. This self-selection of high-risk and seropositive individuals at needle exchange programs has also been observed in San Francisco,<sup>27</sup> Vancouver<sup>28</sup> and Baltimore.<sup>29</sup> It has been interpreted as showing the positive public health impact of such programs in reaching marginalized injection drug users. HIV-positive women were more likely to obtain syringes from shooting galleries than were HIV-negative women. This finding is consistent with results of a study showing that HIV-positive women tend to adopt behaviours that protect their partners more frequently

than they adopt behaviours that protect themselves.<sup>30</sup>

Sexual risk behaviours are difficult to assess in HIV prevalence studies because of their association with high-risk injection behaviours and because of their sex-specific characteristics. Because of the relatively small number of women in our study, we were able to address these issues to only a limited extent. This limitation might account for the fact that some sexual behaviour variables, such as prostitution, appeared to be significant predictors of HIV seropositivity only among men.

Men who reported more than one sexual partner in the previous 6 months were less likely to be seropositive than those reporting no sexual partners. There may be several reasons for this finding, including loss of libido with heavy use of injection drugs and poor general health related directly or indirectly to HIV status. This raises the issue of partner notification and support for HIV-discordant couples, given injection drug use by one or both partners.

Among women, being out of addiction treatment was associated with seropositivity in the multivariate model. We interpreted this finding as suggestive of the difficulty faced by HIV-positive women in accessing addiction services. Overall, only 1152 (42.0%) of injection drug users were in addiction treatment at the time of recruitment into the study. Countries such as Switzerland have established policies to increase accessibility to a variety of programs and have increased the proportion of drug users in contact with treatment resources.<sup>31</sup> The duration of addiction treatment has been associated with a lower incidence of HIV infection,<sup>32</sup> and strategies to increase accessibility and retain high-risk injection drug users in the health system could improve prevention efforts.

Among men, a lifetime history of imprisonment was independently associated with HIV seropositivity, and the risk of infection among those who reported having injected drugs in prison was approximately 2.5 times greater than among those who did not report such activity. In a study conducted in a provincial prison setting, Hankins and associates<sup>33</sup> reported that 73% of men and 15% of women had taken drugs while in prison. In our study a greater proportion of seropositive women than seronegative women reported having had sexual intercourse while in prison. This difference was also observed in New York,<sup>19</sup> where sex with other women was associated with HIV seropositive status among female prison inmates.

As in other studies involving voluntary recruitment, our study has limited potential for generalization. Given the site of the study, it is likely that high-risk and older, long-term injection drug users were overrepresented. Women constituted only about 20% of the study group, as passive recruitment (by word of mouth) was less successful for women than for men. This difference meant that the proportion of women in addiction treatment at baseline was different from the proportion of men. In view of this differential selection, we took a conservative approach and chose not to directly compare men and women.

Another shortcoming is the validity and reliability of self-reported behavioural data among injection drug users, a concern raised in previous studies.<sup>34,35</sup> In the present study, all information was collected in a private room in face-to-face interviews by trained and experienced nurses, who sought to establish a rapport and to build the confidence of participants. To minimize the risk of false reporting of injection drug use, interviewers inspected skin tracks of injections and questioned participants about injection techniques before enrolment in the study.

Finally, this study, unlike incidence studies, should not be used to identify predictors of seroconversion. Rather, its findings present a picture of behaviours encountered in long-term injection drug users of both sexes in Montreal. This information may be useful in identifying the needs of these drug users and in planning interventions.

Injection drug use represents an important source of HIV transmission. Although clean syringes are theoretically accessible, it appears that needle distribution programs have partly failed to alter high-risk situations. Even with the implementation of comprehensive needle exchange programs and outreach work, health care and drug treatment programs have failed to attract and retain injection drug users.

Differences between female and male addicts in terms of interpersonal relationships, use of other substances, drug dealing, legal employment and criminal behaviours often parallel traditional role expectations of the sexes.<sup>36</sup> In this study, we could not directly compare men's and women's behaviours related to HIV infection. However, our data support the hypothesis that risk factors and processes related not only to sexual behaviours, but also to the social contexts of drug use and service utilization, might differ with regard to HIV prevalence among men and women.

Our results raise questions about potential barriers to accessibility for HIV-positive women at pharmacies, needle exchange programs and addiction treatment programs. Women have special needs and fears with regard to their children. Prevention policies for prison inmates, both men and women, should be adapted to specific needs. Finally, along with focused programs such as needle exchange programs, community agencies, outreach and addiction treatment, mainstream services must reach out to and welcome injection drug users and establish a continuum of care from street level to addiction treatment.

*Competing interests:* None declared.

*Contributors:* Dr. Bruneau oversaw the project. She was involved in the data analysis, drafted the paper and participated in revisions. Dr. Lamothe commented on the data analysis; he was involved in writing an early version of the paper and commented on the revisions. Dr. Soto worked on the analytical design, contributed to the interpretation of the results, and was involved in writing the initial version of the manuscript. Ms. Lachance performed most of the statistical analysis and commented on several versions of the manuscript. Dr. Vincelette was responsible for the laboratory testing of the cohort and contributed to the discussion of the results in the paper. Ms. Vassal coordinated the research of the Saint-Luc Cohort and commented on the manuscript. Dr. Franco provided advice at all stages of data analysis and manuscript preparation. He also contributed directly to the writing of the interpretation section.

*Acknowledgements:* This study was supported by the National Health Research and Development Program of Health Canada (6605-2936-AIDS) and by the National Institute of Drug Abuse (R01 DA11591-01). We thank Chantal Clément, Solanges Dion and Diane Labrie, who conducted the interviews, and Elisabeth Deschênes for her assistance in managing the data.

## References

1. Archibald CP, Remis RS, Williams G, Farley J, Albert T, Yan P, et al. Estimating current prevalence and incidence of HIV in Canada [plenary session]. Sixth Annual Canadian Conference on HIV/AIDS Research; May 1997; Ottawa.
2. Division of HIV/AIDS Surveillance, Bureau of HIV/AIDS, STD and Tuberculosis, Laboratory Centre for Disease Control. *HIV and AIDS in Canada. Surveillance report to December 31, 1998*. Ottawa: Health Canada; 1999. p. 30.
3. Anthony JC, Vlahov D, Nelson KE, Cohn S, Astemborski J, Solomon L. New evidence on intravenous cocaine use and the risk of infection with human immunodeficiency virus type 1. *Am J Epidemiol* 1991;134(10):1175-89.
4. Hudgins R, McCusker J, Stoddard A. Cocaine use and risky injection and sexual behaviours. *Drug Alcohol Depend* 1995;37:7-14.
5. Schoenbaum EE, Hartel D, Selwyn P, Klein RS, Davenny K, Rogers M, et al. Risk factors for human immunodeficiency virus infection in intravenous drug users. *N Engl J Med* 1989;321:874-9.
6. Bruneau J, Lamothe F, Franco E, Lachance N, Désy M, Soto J, et al. High rates of HIV infection among injection drug users participating in needle exchange programs in Montreal: results of a cohort study. *Am J Epidemiol* 1997;146(12):994-1002.
7. Chaisson RE, Bachetti P, Osmond D, Brodie B, Sande MA, Moss AR. Cocaine use and HIV infection in intravenous drug users in San Francisco. *JAMA* 1989;261(4):61-5.
8. Patrick DM, Strathdee SA, Archibald CP, Ofner M, Craib KJ, Cornelisse PG, et al. Determinants of HIV seroconversion in injecting drug users during a period of rising prevalence in Vancouver. *Int J STD AIDS* 1997;8(7):437-45.
9. Marmor M, Des Jarlais DC, Cohen H, Friedman SR, Beatrice ST, Dubin N, et al. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. *AIDS* 1987;1:39-44.
10. Lamothe F, Bruneau J, Coates R, Rankin JG, Soto J, Arshinoff R, et al. Sero-prevalence and risk factors for HIV-1 infection in injection drug users in Montreal and Toronto: a collaborative study. *CMAJ* 1993;149(7):945-51.
11. Vlahov D, Munoz A, Anthony DC, Cohn S, Celentano DD, Nelson KE. Association of drug injection patterns with antibody to immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland. *Am J Epidemiol* 1990;132:847-56.
12. Chitwood DD, McCoy CD, Inciardi JA, McBride DC, Comerford M, Trapido E, et al. HIV seropositivity of needles from shooting galleries in south Florida. *Am J Public Health* 1990;80:150-2.
13. Moss AR, Vranizan K, Gorter R, Bacchetti P, Watters J, Osmond D. HIV seroconversion in intravenous drug users in San Francisco, 1985-1990. *AIDS* 1994;8:223-31.
14. Saxon AJ, Calsyn DA, Whittaker S, Freeman G Jr. Sexual behaviours of intravenous drug users in treatment. *J Acquir Immune Defic Syndr* 1991;4(10):938-44.
15. Van den Hoek JAR, van Haastrecht HJA, Scheeringa-Troost B. HIV infection and STD in drug-addicted prostitutes in Amsterdam: potential for heterosexual transmission. *Genitourin Med* 1989;65:146-50.
16. Joe GW, Simpson DD. HIV risks, gender, and cocaine use among opiate users. *Drug Alcohol Depend* 1995;37(1):23-8.
17. Siegal HA, Carlson RG, Falck R, Li L, Forney MA, Rapp RC, et al. HIV infection and risk behaviors among intravenous drug users in low seroprevalence areas in the Midwest. *Am J Public Health* 1991;81(12):1642-44.
18. Latkins C, Mandell W, Vlahov D, Oziemkowska M, Celentano D. People and places: behavioural settings and personal network characteristics as correlates of needle sharing. *J Acquir Immune Defic Syndr* 1996;13:273-80.
19. Friedman SR, Jose B, Deren S, Des Jarlais DC, Neagus A. Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. *Am J Epidemiol* 1995;142(8):864-75.
20. Davies AG, Dominy NJ, Peters A, Burns SM, Richardson AM. HIV in injecting drug users in Edinburgh: prevalence and correlates. *J Acquir Immune Defic Syndr* 1995;8:399-405.
21. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, et al. Intersecting epidemics — crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. *New Engl J Med* 1994;331(21):1422-7.
22. Rhodes T, Stimson GV. What is the relationship between drug taking and sexual risk? Social relations and social research. *Social Health Illness* 1994;16:209-20.
23. Donoghoe MC. Sex, HIV and injecting drug users. *Br J Addict* 1992;87:405-16.
24. Klee H. HIV risks for women drug injectors: heroin and amphetamine users compared. *Addiction* 1993;88:1055-62.
25. Davies AG, Dominy NJ, Peters AD, Richardson AM. Gender differences in HIV risk behaviour of injecting drug users in Edinburgh. *AIDS Care*

- 1996;8(5):517-27.
26. Brook DW, Brook JS, Whiteman M, Win PT, Gordon-Maloul C, Roberto J, et al. Psychosocial risk factors for HIV transmission in female drug abusers. *Am J Addict* 1997;6(2):124-34.
  27. Hahn JA, Vranizan KM, Moss AR. Who uses needle exchange? A study of injection drug users in treatment in San Francisco, 1989-1990. *J Acquir Immune Defic Syndr Hum Retroviral* 1997;15(2):157-64.
  28. Schechter MT, Strathdee SA, Cornelisse PG, Currie S, Patrick DM, Rekart ML, et al. Do needle exchange programmes increase the spread of HIV among injection drug users? An investigation of the Vancouver outbreak. *AIDS* 1999;13(6):F45-51.
  29. Vlahov D, Junge B. The role of needle exchange programs in HIV prevention. *Public Health Rep* 1998;113(Suppl 1):75-80.
  30. Gollub EL, Rey D, Obadia Y, Moatti JP. Gender differences in risk behaviors among HIV+ persons with an IDU history. The link between partner characteristics and women's higher drug-sex risks. The Manif 2000 Study Group. *Sex Transm Dis* 1998;25(9):483.
  31. Gervasoni JP, Dubois-Arber F, Bennighoff F. Évaluation des mesures de la Confédération destinées à réduire les problèmes liés à la toxicomanie. Rapport de synthèse 1990-1996. Lausanne, Switzerland: Institut universitaire de médecine sociale et préventive; 1997.
  32. Van Ameijden EJC, Van Den Hoek JAR, Coutinho RA. Injecting risk behaviours among drug users in Amsterdam, 1986 to 1992, and its relationship to AIDS prevention programs. *Am J Public Health* 1994;84:275-81.
  33. Hanks CA, Gendron S, O'Shaughnessy MV. Risk factors for HIV infection in inmates of medium security correctional institutions: Montreal 1990-1992. Final report. Montreal: Direction de la santé publique, Régie régionale de la santé et des services sociaux de Montréal-Centre; 1995.
  34. Latkin CA, Vlahov D, Anthony JC. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. *Addiction* 1993;88:517-26.
  35. Falck R, Siegal HA, Forney MA. The validity of injection drug users' self-reported use of opiates and cocaine. *J Drug Issues* 1992;22(4):823-32.
  36. Anglin MD, Hser YI, McGlothlin WH. Sex differences in addict careers. 2. Becoming addicted. *Am J Drug Alcohol Abuse* 1987;13(1-2):59-71.

**Reprints requests to:** Dr. Julie Bruneau, Centre hospitalier de l'Université de Montréal, Hôpital Saint-Luc, 1058 Saint-Denis, Montréal QC H2X 3J4; fax 514 281-2181; julie.bruneau@umontreal.ca

## How you can get involved in the CMA!

The CMA is committed to providing leadership for physicians and promoting the highest standard of health and health care for Canadians. To strengthen the Association and be truly representative of all Canadian physicians, the CMA needs to hear from members interested in serving in elected positions and on appointed committees and advisory groups.

The CMA structure comprises both governing bodies and advisory bodies either elected by General Council or appointed by the CMA Board of Directors. The Board of Directors - elected by General Council - has divisional, affiliate, resident and student representation, is responsible for the overall operation of the CMA and reports to General Council on issues of governance. CMA councils and committees advise the Board of Directors and make recommendations on specific issues of concern to physicians and the public. Four core councils and committees consist of either divisional or regional representation while other statutory and special committees, expert working and project advisory groups comprise individuals with interest and expertise in subject-specific fields. Positions on one or more of these committees may become available in the coming year.

For further information on how you can get involved, please contact:

**Patricia Trunzo**  
**Core Advisory Services Officer, Corporate Affairs**  
**Canadian Medical Association**  
**1867 Alta Vista Drive**  
**Ottawa, ON K1G 3Y6**  
**Fax: (613) 526-7570**  
**Tel. 1-800-663-7336, ext. 1113**  
**Email: trunzp@cma.ca**

By getting involved, you will have an opportunity to make a difference.

We hope to hear from you.

## Comment vous pouvez participer à l'AMC!

L'AMC est vouée à jouer un rôle de chef de file auprès des médecins et à promouvoir les normes les plus élevées de santé et de soins de santé pour les Canadiens. Afin de renforcer l'Association et pour qu'elle représente véritablement tous les médecins du Canada, l'AMC a besoin de membres intéressés à occuper des charges élues et à siéger à des comités et des groupes consultatifs.

La structure de l'AMC est composée d'organes de régie élus par le Conseil général et d'entités consultatives nommées par le Conseil d'administration. Le CA, dont les membres sont élus par le Conseil général, réunit des représentants des divisions, des sociétés affiliées, des résidents et des étudiants en médecine et est chargé de l'administration générale de l'AMC. Il rend compte de questions de régie au Conseil général. Les conseils et les comités de l'AMC jouent le rôle de conseillers auprès du Conseil d'administration et présentent des recommandations au sujet de questions particulières qui intéressent les médecins et la population. Quatre conseils et comités principaux sont constitués de représentants des divisions et des régions, tandis que les autres comités statutaires et spéciaux, les groupes d'experts et les groupes consultatifs de projets réunissent des personnes qui s'intéressent à des sujets précis et possèdent des compétences spécialisées. Des postes pourront devenir vacants dans un ou plusieurs de ces comités en cours d'année.

Pour en savoir davantage sur les modalités de participation, veuillez communiquer avec

**Patricia Trunzo**  
**Agente, Services aux structures consultatives,**  
**Affaires générales**  
**Association médicale canadienne**  
**1867, promenade Alta Vista**  
**Ottawa (Ontario) K1G 3Y6**  
**Télec. : (613) 526-7570**  
**Tél. : 1-800-663-7336, poste 1113**  
**Courriel : trunzp@cma.ca**

Votre participation peut faire la différence.

Nous espérons avoir de vos nouvelles!